Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

November brought a mix of regulatory milestones, late-phase clinical insights, and evolving digital health trends across 

. From the US Food & Drug Administration’s (FDA) first clearance of Deep Transcranial Magnetic Stimulation (Deep TMS) for adolescents with

to a New Drug Application (NDA) filing that could introduce a novel ADHD mechanism of action, the month highlighted both therapeutic innovation and shifting treatment paradigms.

Clinicians also saw new phase 4 data on adjunctive perospirone for treatment-resistant depression and fresh evidence revealing the engagement challenges of mental health apps. Here are 4 psychiatry headlines you may have missed.

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

The FDA has cleared BrainsWay’s Deep TMS system for adolescents aged 15 - 21 years with major depressive disorder (MDD), expanding its previous approval for adults aged 22–86. This decision marks the first clearance of Deep TMS for a younger population that often has limited effective treatment options.

The expanded indication was supported by one of the largest real-world adolescent neuromodulation datasets submitted to the FDA, demonstrating substantial reductions in depressive and anxiety symptoms. In the supporting study, participants completed 36 sessions of either high-frequency Deep TMS or intermittent theta-burst stimulation, achieving a mean 12.1-point improvement on the PHQ-9 and a 66.1% response rate. Treatment consists of noninvasive magnetic stimulation delivered through a cushioned helmet in 20-minute daily sessions over 4–6 weeks. Adverse events were mild and consistent with adult data, most commonly headaches and localized discomfort.

Deep TMS is also FDA-cleared for OCD, anxious depression, and smoking cessation.

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Otsuka Pharmaceuticals has submitted an NDA to the FDA for centanafadine, a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) for treating ADHD in patients aged 4 – 55 years. The NDA is supported by 4 pivotal phase 3 trials evaluating once-daily, extended-release centanafadine across children, adolescents, and adults. In these studies, centanafadine produced statistically significant and clinically meaningful reductions in ADHD symptoms compared with placebo, measured by ADHD-RS-5 in younger patients and AISRS in adults.

High-dose treatment consistently showed the strongest effects, including significant improvements in children aged 4 - 12 years and adolescents aged 13 – 17 years, while both 200 mg and 400 mg doses were effective in adults. The medication was generally well tolerated; common adverse events included decreased appetite, nausea, rash, fatigue, and abdominal pain. The study observed somnolence in younger patients and decreased appetite and headache in adults.

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Phase 4 trial results show perospirone is safe and well-tolerated as adjunctive therapy for MDD over 8 weeks, with potential, but inconclusive, efficacy benefits. The study enrolled 210 patients with inadequate response to SSRIs or SNRIs, randomized to perospirone or placebo added after 4 weeks of antidepressant treatment. While remission rates were greater with perospirone (55.2% vs 38.9%), response rates were similar between groups. Investigators noted a high placebo response, and expectancy effects may have reduced the observed drug-placebo difference. Overall, early adjunctive perospirone may offer benefit, but efficacy findings remain preliminary and require further study.

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

A meta-analysis of 79 RCTs found that mental health apps achieve high uptake (92%) but only moderate adherence, with many users failing to complete follow-up assessments. Engagement improved with reminders and human support, while gamification did not boost retention. Across trials, 62% of users continued using apps, though real-world uptake is likely far lower.

Attrition rates ranged from 19% during treatment to 28% at follow-up, similar to dropout levels in psychotherapy and pharmacotherapy. Investigators noted that accountability features reduce attrition, and clinicians can use these insights to guide app recommendations and set realistic expectations for patients.

Articles

November saw significant developments in psychiatry, including FDA clearance of Deep TMS for adolescents with MDD and an NDA submission for a novel ADHD treatment. Phase 4 data on adjunctive perospirone for treatment-resistant depression showed safety and potential efficacy, though results were inconclusive. Mental health apps demonstrated high uptake but faced challenges with adherence and retention, highlighting the need for improved engagement strategies. These advancements underscore the ongoing evolution of therapeutic options and digital health trends in psychiatry, offering new insights and opportunities for clinicians and patients alike.

This month in review highlights November’s biggest psychiatry stories, including FDA moves, phase 4 findings, and new data on digital mental health tools.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

4 Psychiatry Headlines You Missed in November

Ozlem Bilen, MD, is an associate professor of medicine in the cardiology division and chief of cardiology at Emory University Hospital.

Mavacamten Monotherapy Improves Cardiac Function in oHCM, With Ozlem Bilen, MD

Mavacamten monotherapy has proven its efficacy in improving cardiac function and symptoms in patients with 

obstructive hypertrophic cardiomyopathy (HCM)

, according to data from the COLLIGO-HCM trial.

Mavacamten has long been known to improve cardiac function and symptoms in patients with HCM; several clinical studies have indicated its efficacy and favorable safety profile. However, little literature exists regarding monotherapy in real-world studies.

 met with Ozlem Bilen, MD, associate professor of medicine in the cardiology division and chief of cardiology at Emory University Hospital, to discuss the implications of these data, highlighting the potential of mavacamten monotherapy in patients with HCM.

“When we looked into the improvements in NYHA class, about 60% of patients in mavacamten monotherapy and 61% of patients in background medical therapy had improved their NYHA class by ≥1 class,” Bilen told 

. “And when we looked into the changes in LVOT gradients, we saw significant improvement in both groups as well. About 94% in monotherapy and 87% in the background therapy group have reached resting LVOT gradients of <30, which is the threshold used to define obstructive HCM.”

COLLIGO-HCM is an ongoing retrospective, observational, multicenter, international study, the study period of which ran from April 2022 to February 2025. Investigators collected data from 7 participating sites in 5 countries across 4 continents. To be included, patients were required to have ≥1 encounter with an HCM diagnosis during or after 2018 and be aged ≥18 years at the index date. Patients were excluded if they had an HCM phenocopy observed after the first HCM-associated encounter in the medical record.

Investigators assessed longitudinal measurements of NYHA class, resting and Valsalva LVOT gradients, and LVEF throughout the trial. Safety outcomes included the proportion of patients who interrupted or permanently discontinued treatment due to an LVEF <50%, a label-mandated trigger for interruption of mavacamten treatment in routine clinical practice to avoid signs and symptoms of systolic dysfunction. In these instances, investigators took echocardiogram measurements at subsequent visits after interruption to confirm LVEF recovery to ≥50%.

A total of 278 patients received mavacamten during the study period; of these, 20 received mavacamten monotherapy at baseline and 68 received mavacamten monotherapy after discontinuing background therapy. Additionally, 190 patients received mavacamten with down-titrated background therapy or background therapy without dose modification. The mean follow-up length was 35 weeks for the overall cohort, 41.4 weeks for the mavacamten monotherapy subgroup, and 32 weeks for the mavacamten with background therapy subgroup.

By month 9, roughly 60% of patients exhibited a NYHA improvement of ≥1 class from baseline (45 of 75 patients; 

 <.0001) in the mavacamten monotherapy subgroup and 61% (89 of 146 patients; 

 <.0001) in the mavacamten with background therapy subgroup. No patients in the mavacamten subgroup and 1 patient in the background therapy subgroup exhibited worsened NYHA by ≥1 class at 9 months from baseline. Significant improvements in resting LVOT gradients were also observed in both subgroups at every measured timepoint; mean change from baseline to month 9 was -35.5 mmHg in the mavacamten monotherapy subgroup and -30.3 mmHg in the mavacamten background therapy subgroup (

Mean LVEF remained ≥62% in the monotherapy subgroup and 61.4% in the background therapy subgroup through month 9. The mean change in LVEF was -3.2% in the monotherapy group and -5% in the background therapy group. Roughly 4% (11 of 278) of patients in the overall cohort interrupted therapy due to an LVEF <50%; 5 of these patients were in the monotherapy group and 6 in the background therapy group. Of these 11 patients, 10 had their LVEF recover after treatment interruption.

Mavacamten monotherapy was ultimately associated with improvements in cardiac function and symptoms, and positive benefits to the risk profile over the 9-month follow-up period. Investigators noted consistency with improvements observed in patients treated with mavacamten and background therapy.

“I think the main takeaway from this cohort and other clinical trial evidence is that mavacamten monotherapy is efficacious and quite safe, overall,” Bilen said. “And it is also safe to discontinue background medical therapy. I think in the long run, we will probably see a guideline update.”

Editor's Note: Bilen reports disclosures with Bristol-Myers Squibb and Cytokinetics.

Bilen O, Adler AS, Bastiaenen R, et al. Mavacamten monotherapy in real-world patients with obstructive hypertrophic cardiomyopathy: Evidence from Colligo-HCM. Circulation: Genomic and Precision Medicine. Published online November 10, 2025. 

Bristol-Myers Squibb. COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) (COLLIGO-HCM). ClinicalTrials.gov Identifier: NCT06372457. Updated April 18, 2024. Accessed December 3, 2025. 

https://clinicaltrials.gov/study/NCT06372457

Videos

Bilen discusses the COLLIGO-HCM trial, investigating the real-world efficacy of mavacamten monotherapy for patients with obstructive HCM.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Cardiomyopathy

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

The month of November 2025 saw a wide array of notable events take place in the field of 

, and many of these headlines were covered by the 

In November’s iteration of the Month in Review series, 

 has listed 8 significant headlines of note in the skin health space. The list includes news covered in November regarding treatments such as risankizumab and upadacitinib, as well as 

 news regarding roflumilast cream 0.3% for children with atopic dermatitis.

Additionally, this review highlights several notable interviews and other news released following 3 conferences: the 

Society of Dermatology Physician Associates (SDPA) Fall Conference

 in Texas, the American College of Allergy, Asthma, & Immunology (ACAAI) Annual Scientific Meeting in Florida, and the 

 in Nevada. The following list provides key updates on developments in dermatology:

Risankizumab Effective as Treatment for Psoriasis in Genital, Scalp Regions

In 1 story covered in November 2025, new data showed risankizumab could be an efficacious and safe therapy for patients with moderate-to-severe psoriasis in the genital and scalp regions. This conclusion was the result of phase 4 findings in an analysis authored by such investigators as Eingun James Song, MD, director of clinical research at Frontier Dermatology. Song et al’s UnlIMMited study found, in addition to the higher clearance rates observed with risankizumab versus placebo, no new safety signals for the drug, supporting its use in sensitive psoriasis regions.

OX40/OX40 Ligand Target Offers Broader Acting Therapy for Atopic Dermatitis, With Raj Chovatiya, MD, PhD

During the 2025 ACAAI Annual Scientific Meeting in Orlando, Florida, Raj Chovatiya, MD, PhD, of Northwestern University’s Feinberg School of Medicine, spoke with the 

 team about his talk, ‘7 for 11: Hot Therapeutic Targets in Allergy and Immunology.’ He highlighted takeaways from his session on OX40/OX40L, otherwise known as the interaction between the costimulatory TNF receptor OX40 and its ligand, OX40L, and its role in atopic conditions.

Treating Dermatology Patients with Off-Label JAK Inhibitors, With Gabriela Maloney, DO

During the SDPA Fall Conference in San Antonio, the 

 team spoke with Gabriela Maloney, DO, a board-certified dermatologist at Forefront Dermatology, about her conference session titled ‘Off-Label Usage of JAK Inhibitors.’ Ever since ruxolitinib cream’s FDA approval in 2021, making this topical treatment the first Janus kinase (JAK) inhibitor approved in dermatology, JAK inhibitors have seen expansions in their use. Maloney highlighted off-label JAK inhibitors’ use in a variety of conditions, pointing, for example, to bullous diseases such as bullous pemphigoid, pemphigus vulgaris, lichen planus erosive lichen planus, and cicatricial alopecia.

Guidelines Presented on Managing Genetic Skin Disorders and Referring Patients

Another story highlighted at the SDPA Fall Conference highlighted coverage of a session at the meeting titled ‘The ABCs of Genetic Disorders of the Skin: Guidelines for Recognition and When to Refer.’ Presented by Yasmine Kirkorian, MD, the chief of the Division of Pediatric Dermatology at Children’s National Hospital (CNH), this talk reviewed several commonly observed genetic syndromes with cutaneous manifestations. These included tuberous sclerosis, neurofibromatosis type 1, and others. During her session, Kirkorian emphasized the recognition of skin findings resulting in a referral to a geneticist or a specialty clinic.

Discussing New Topical Drugs for Atopic Dermatitis in Younger Patients, With Peter Lio, MD

In an interview conducted during the 2025 Fall Clinical Dermatology Conference, Peter A. Lio, MD, a clinical professor of Dermatology at the Icahn School of Medicine at Mount Sinai and clinical assistant professor of Dermatology & Pediatrics at Northwestern University’s Feinberg School of Medicine, spoke on several notable takeaways from his sessions at the meeting in Las Vegas. In this interview, Lio highlighted news on several treatments in the armamentarium, such as topical ruxolitinib, a JAK inhibitor, and its approval down to the age of 2 years. He also discussed topical tapinarof, an aryl hydrocarbon receptor agonist, and its recent age expansion.

FDA Accepts sNDA for Roflumilast Cream 0.3% in Children Ages 2 to 5 with Psoriasis

The FDA’s acceptance of a supplemental New Drug Application (sNDA) for roflumilast (Zoryve) cream 0.3% for children aged 2-5 years with psoriasis was also highlighted in November, potentially leading to an expansion in this drug’s indication. The drug was designed as a once-daily, advanced targeted topical phosphodiesterase-4 (PDE4) inhibitor. The November 17 announcement by Arcutis Biotherapeutics, Inc. highlighted a PDUFA target action date of June 29, 2026, for roflumilast cream’s approval for this new age range.

SCALE-UP: Findings on Real-World Use of Upadacitinib in Atopic Dermatitis

Other findings highlighted in November had been presented at the 2025 Fall Clinical Dermatology Conference, including new real-world data on upadacitinib’s use in atopic dermatitis. The findings, authored by such investigators as Jonathan Silverberg, MD, PhD, MPH, associate professor of Dermatology at The George Washington University School of Medicine and Health Sciences, resulted from the SCALE‐UP study. In their analysis, Silverberg et al pointed to upadacitinib’s significant clinical benefits in treating moderate-to-severe atopic dermatitis, highlighting the rapid reductions in itch and the rapid skin clearance seen in both AST-naïve and AST-experienced patients.

ARCADIA LTE: Long-term Nemolizumab Effective in Adolescents with Atopic Dermatitis

In other data covered at the Fall Clinical conference, treatment of adolescent patients with atopic dermatitis via nemolizumab 30 mg every 4 weeks (Q4W), along with a background of topical corticosteroids (TCS) of low/medium potency with/without topical calcineurin inhibitors (TCI), was shown to have improved key signs and symptoms. These findings resulted from a post hoc analysis from ARCADIA LTE and were authored by such investigators as Adam Reich, MD, PhD, a full-time professor at the Department of Dermatology, University of Rzeszów, Poland.

November 2025 witnessed significant developments in dermatology, with key updates on treatments and FDA news. Risankizumab showed efficacy for psoriasis in sensitive regions, while OX40/OX40L emerged as a promising target for atopic dermatitis. Off-label JAK inhibitors were discussed for various dermatological conditions. New guidelines for managing genetic skin disorders were presented, and advancements in topical drugs for younger patients were highlighted. The FDA accepted an sNDA for roflumilast cream for young children with psoriasis. Real-world data on upadacitinib and long-term efficacy of nemolizumab in adolescents with atopic dermatitis were also reported.

This review of November 2025 highlights several notable news stories covered in the dermatology space.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

8 Dermatology Headlines You Missed in November 2025

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

New research provides insights into the distinct stage-specific progression patterns and identifiable risks of sarcopenia among older adults undergoing maintenance hemodialysis (MHD).

“This study revealed differences in body composition, physical activity levels, nutritional status, and self-management abilities across different stages of sarcopenia in MHD patients, highlighting the importance of early identification and intervention,1” wrote study investigator Jinguo Li, a student and intern at the research center of clinical laboratory sciences at Bengbu Medical University, and colleagues.

Older adults receiving maintenance hemodialysis (MHD) commonly experience protein-energy wasting, chronic inflammation, dialysis-related metabolic disturbances, reduced physical activity, and psychosocial stressors. Together, these factors accelerate muscle loss and functional decline, placing this population at heightened risk for sarcopenia.

Findings from this multicenter cross-sectional study highlight the importance of early screening and preventive strategies in aging MHD populations, suggesting clinicians can integrate improved nutrition, physical activity, and self-efficacy interventions to delay sarcopenia progression and promote healthy aging.

The Asian Working Group for Sarcopenia’s (AWGS) 2019 consensus introduced the concept of possible sarcopenia, defined as reduced muscle strength and/or physical function in the setting of preserved muscle mass. Because this stage is considered potentially reversible, prior research has emphasized its importance as a target for early intervention. However, data on its prevalence, clinical implications, and progression among patients receiving MHD remain limited.

Li and colleagues evaluated sarcopenia in a study that enrolled 448 older adults ≥ 60 years of age receiving maintenance hemodialysis 2-3 times per week for ≥3 months, with each session lasting 4 hours and a blood flow rate of no less than 200 mL/min from 3 tertiary hospitals in Bengbu, China.

To evaluate sarcopenia, they applied AWGS 2019 staging criteria, which incorporate assessments of muscle mass, muscle strength, and physical function and conducted routine surveys before patients’ mid-week dialysis, including a modified quantitative subjective global assessment (MQSGA) for nutritional status, an International Physical Activity Questionnaire (IPAQ-SF) to assess physical activity, and the self-efficacy for managing chronic disease 6-item scale (SES6).

Investigators categorized sarcopenia into 3 stages:

Possible Sarcopenia: a decline in muscle strength and/or physical function, but muscle mass is not yet reduced.

Confirmed Sarcopenia: low skeletal muscle mass is combined with either muscle strength decline or physical function reduction.

Severe Sarcopenia: low skeletal muscle mass, muscle strength decline, and physical function reduction.

Patients without sarcopenia were classified as the control (n = 206), and those with possible or confirmed sarcopenia as the case group (n = 242).

At baseline, patients with sarcopenia had a significantly higher proportion of female participants (47.1% vs 34.0%; 

 = .005), a longer median dialysis vintage (55.5 [26.0–83.0] months vs 35.0 [16.75–56.0] months; 

 <.001), and a lower basal metabolic rate (1294 kcal/d vs 1503 kcal/d; 

 <.001) compared to patients without sarcopenia.

In the multivariable model, several factors were independently protective against sarcopenia. Although more women appeared in the sarcopenia group in unadjusted analyses, this reversed after adjustment, with female sex emerging as a protective factor (OR, 0.023; 95% CI, 0.001-0.402; 

= .010). Higher self-efficacy (OR, 0.129; 95% CI, 0.062-0.269; 

<.001), higher basal metabolic rate (OR, 0.987; 95% CI, 0.976-0.998; 

 = .023), and higher BMI (OR, 0.738; 95% CI, 0.565-0.962; 

Investigators also quantified risk increases associated with declines in these factors. Each 1-point decrease in SES6 score increased the risk of sarcopenia progression by approximately 44% (OR, 0.558; 95% CI, 0.344-0.903; 

 = .018). For every 100-kcal/d increase in BMR, the risk increased by about 4.8% (OR, 1.048; 95% CI, 1.004-1.092; 

 = .042). A 1-kg/m² decrease in BMI increased the risk by approximately 51% (OR, 0.492; 95% CI, 0.378-0.646; 

The identified significant risk factors for sarcopenia included comorbid diabetes (OR, 4.639; 95% CI, 1.061-20.275; 

 = .041), longer dialysis vintage (OR, 1.025; 95% CI, 1.005-1.045; 

 = .013), poorer nutritional status based on MQSGA score (OR, 2.778; 95% CI, 1.710-5.450; 

 <.001), and low physical activity level (IPAQ) (low vs high: OR, 26.307; 95% CI, 2.802-247.004; 

Notably, the risk associated with low physical activity exceeded a 50-fold increase compared with high activity levels (OR, 54.722; 95% CI, 2.224-962.841; 

“The findings collectively demonstrate significant associations between sarcopenia in MHD patients and nutritional, behavioral, and psychosocial factors. MQSGA, IPAQ-SF, and SES6 reflect these distinct dimensions, together providing a multidimensional understanding of sarcopenia risk,” Li and colleagues concluded.1 “Although the cross-sectional design precludes causal inferences, these findings offer valuable insights: incorporating these assessment tools into routine clinical monitoring may facilitate early identification and risk stratification of high-risk populations.”

Li J, Wang F, Song L, Fang F, Shen M, Wang H. Stage-specific prevalence and progression of sarcopenia among aging hemodialysis patients: a multicenter cross-sectional study. 

. 2025;13:1676139-1676139. doi:https://doi.org/10.3389/fpubh.2025.1676139

‌Chen LK, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. 

Journal of the American Medical Directors Association

. 2020;21(3):300-307.e2. doi:https://doi.org/10.1016/j.jamda.2019.12.012

Research highlights the progression patterns and risks of sarcopenia in older adults on maintenance hemodialysis (MHD). The study emphasizes early identification and intervention, noting differences in body composition, physical activity, nutrition, and self-management across sarcopenia stages. Factors like protein-energy wasting, chronic inflammation, and reduced activity heighten sarcopenia risk. Protective factors include higher self-efficacy, basal metabolic rate, and BMI. Risk factors include diabetes, longer dialysis vintage, poor nutrition, and low physical activity. The study suggests integrating nutritional, physical, and self-efficacy interventions to delay sarcopenia progression.

A multicenter study outlines stage-specific risk factors, protective traits for sarcopenia in older adults on maintenance hemodialysis, supporting earlier screening.


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Risk Factors for Sarcopenia in Older Adults on MHD Include Physical Activity, Nutrition

Benefits of Oral BTKi Administration in CSU

Jason Hawkes, MD, MS, a board-certified dermatologist and associate professor of Dermatology at the University of California Davis outlines the mechanistic rationale for using oral BTK inhibitors, such as remibrutinib, in CSU. He notes remibrutinib’s selective inhibition of Bruton tyrosine kinase—central to mast cell activation—and its rapid, robust effect on both superficial and deep urticarial manifestations, including angioedema.

According to Hawkes, remibrutinib offers particular benefit to patients who have failed, are intolerant of, or are not candidates for antihistamines, omalizumab, or dupilumab. Its oral route confers convenience, making it well-suited for individuals already managing multiple medications or those averse to injectable therapies. Clinical improvements appear to be independent of baseline IgE levels, broadening its applicability across varied patient phenotypes.

Hawkes advises that the choice of remibrutinib can also be informed by unique patient characteristics, such as previous intolerance to other therapies, lifestyle considerations, and preference for oral versus injectable medications. He emphasizes that its rapid onset, broad efficacy, and safety profile support its integration into the therapeutic armamentarium for CSU.

Jason Hawkes, MD, MS details the clinical advantages and patient populations best suited for oral BTK inhibitor therapy, such as remibrutinib, in CSU.


Video Series

Amanda Armstrong, MD, MPH, predicts a move toward mechanism-based therapy selection and highlights biomarkers that could guide personalized treatment.

Personalizing CSU Management and the Role of Multidisciplinary Care

A conclusion emphasizing the importance of translating clinical research into everyday practice and continuing innovation to improve patient quality of life and long-term outcomes.

Combination Therapies for IBD and Future Outlook

Non-Cranial Symptoms in GCA

Jason Hawkes, MD, MS examines how adherence, patient expectations, and access barriers influence management and treatment sequencing in CSU.


Impact of Adherence on CSU Management

Forward-looking perspectives on how predictive biomarkers, genetic profiling, and precision tools will guide individualized IBD management in the coming years.

Role of IL-12/IL-23 Inhibitors in the Treatment Landscape of IBD

Discussion on factors such as comorbidities, adherence, and access that influence the choice between oral BTK inhibitors and injectable biologics.

Defining the Role of BTKi in CSU Treatment Algorithms

Current Gaps in Diagnostic Criteria Standards: Key Factors That Inform Diagnostic Decisions 

Hanania explains how IL-33 inhibitors including itepekimab and astegolimab may uniquely benefit COPD exacerbation.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Prospecting the IL-33 Pathway for COPD Care, with Nicola Hanania, MD, MS

Gibson discusses the promising improvements to the composite primary endpoint of mortality, stroke, and recurrent MI as a result of zalunfiban treatment.

Arrhythmia

CeleBrate: Zalunfiban Administration at First Contact Improves STEMI Outcomes, With C. Michael Gibson, MD

Hersh Shroff, MD, MPA, is a transplant hepatologist and an assistant professor of medicine at the University of North Carolina School of Medicine

Recent advancements in hepatology highlight new medications for metabolic dysfunction and liver diseases, promising improved patient outcomes and treatment options.

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

Latest News

4 Psychiatry Headlines You Missed in November

Mavacamten Monotherapy Improves Cardiac Function in oHCM, With Ozlem Bilen, MD

8 Dermatology Headlines You Missed in November 2025

Risk Factors for Sarcopenia in Older Adults on MHD Include Physical Activity, Nutrition

Benefits of Oral BTKi Administration in CSU